Vaughan David Investments LLC Amgen Inc Transaction History

Vaughan David Investments LLC

  • $3.95 Billion
  • Q2 2024

A detailed history of Vaughan David Investments LLC transactions in Amgen Inc stock. As of the latest transaction made, Vaughan David Investments LLC holds 175,610 shares of AMGN stock, worth $56.7 Million. This represents 1.39% of its overall portfolio holdings.

Number of Shares
175,610
Previous 175,160 0.26%
Holding current value
$56.7 Million
Previous $49.8 Million 10.18%
% of portfolio
1.39%
Previous 1.24%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024
BUY
$262.75 - $319.31 $118,237 - $143,689
450 Added 0.26%
175,610 $54.9 Million
Q1 2024

May 13, 2024
SELL
$268.87 - $324.56 $65,873 - $79,517
-245 Reduced 0.14%
175,160 $49.8 Million
Q4 2023

Jan 29, 2024
BUY
$255.7 - $288.46 $15,853 - $17,884
62 Added 0.04%
175,405 $50.5 Million
Q3 2023

Nov 07, 2023
BUY
$218.65 - $271.46 $287,962 - $357,512
1,317 Added 0.76%
175,343 $47.1 Million
Q2 2023

Aug 02, 2023
BUY
$214.27 - $253.37 $192,414 - $227,526
898 Added 0.52%
174,026 $38.6 Million
Q1 2023

May 02, 2023
SELL
$225.79 - $275.2 $142,021 - $173,100
-629 Reduced 0.36%
173,128 $41.9 Million
Q4 2022

Feb 07, 2023
SELL
$229.03 - $291.01 $308,274 - $391,699
-1,346 Reduced 0.77%
173,757 $45.6 Million
Q3 2022

Nov 14, 2022
BUY
$224.46 - $253.15 $205,380 - $231,632
915 Added 0.53%
175,103 $39.5 Million
Q2 2022

Aug 11, 2022
BUY
$230.71 - $256.74 $173,032 - $192,555
750 Added 0.43%
174,188 $42.4 Million
Q1 2022

May 09, 2022
BUY
$219.27 - $242.57 $317,283 - $350,998
1,447 Added 0.84%
173,438 $41.9 Million
Q4 2021

Feb 10, 2022
BUY
$198.88 - $227.6 $203,255 - $232,607
1,022 Added 0.6%
171,991 $38.7 Million
Q3 2021

Nov 04, 2021
SELL
$212.27 - $248.7 $53,067 - $62,175
-250 Reduced 0.15%
170,969 $36.4 Million
Q2 2021

Aug 11, 2021
BUY
$233.58 - $259.14 $462,721 - $513,356
1,981 Added 1.17%
171,219 $41.7 Million
Q1 2021

May 14, 2021
SELL
$221.91 - $258.6 $183,741 - $214,120
-828 Reduced 0.49%
169,238 $42.1 Million
Q4 2020

Feb 12, 2021
BUY
$216.38 - $257.67 $192,794 - $229,583
891 Added 0.53%
170,066 $39.1 Million
Q3 2020

Nov 12, 2020
SELL
$234.65 - $260.95 $128,353 - $142,739
-547 Reduced 0.32%
169,175 $43 Million
Q2 2020

Aug 07, 2020
BUY
$197.81 - $242.74 $201,766 - $247,594
1,020 Added 0.6%
169,722 $40 Million
Q1 2020

May 13, 2020
SELL
$182.24 - $241.7 $687,044 - $911,209
-3,770 Reduced 2.19%
168,702 $34.2 Million
Q4 2019

Feb 13, 2020
SELL
$189.21 - $243.2 $168,018 - $215,961
-888 Reduced 0.51%
172,472 $41.6 Million
Q3 2019

Nov 13, 2019
BUY
$174.11 - $208.62 $272,830 - $326,907
1,567 Added 0.91%
173,360 $33.5 Million
Q2 2019

Aug 14, 2019
BUY
$166.7 - $195.41 $577,448 - $676,900
3,464 Added 2.06%
171,793 $31.7 Million
Q1 2019

May 08, 2019
BUY
$180.87 - $203.88 $300,786 - $339,052
1,663 Added 1.0%
168,329 $32 Million
Q4 2018

Feb 08, 2019
SELL
$178.4 - $208.25 $342,884 - $400,256
-1,922 Reduced 1.14%
166,666 $32.4 Million
Q3 2018

Nov 13, 2018
SELL
$185.29 - $208.89 $51,325 - $57,862
-277 Reduced 0.16%
168,588 $34.9 Million
Q2 2018

Aug 14, 2018
SELL
$166.05 - $186.51 $694,587 - $780,171
-4,183 Reduced 2.42%
168,865 $31.2 Million
Q1 2018

May 04, 2018
BUY
$169.43 - $198.0 $270,918 - $316,602
1,599 Added 0.93%
173,048 $29.5 Million
Q4 2017

Feb 13, 2018
BUY
$168.79 - $188.59 $412,691 - $461,102
2,445 Added 1.45%
171,449 $29.8 Million
Q3 2017

Nov 08, 2017
SELL
$167.29 - $191.0 $274,522 - $313,431
-1,641 Reduced 0.96%
169,004 $31.5 Million
Q2 2017

Aug 14, 2017
BUY
N/A
170,645
170,645 $29.4 Million

Others Institutions Holding AMGN

# of Institutions
3,054
Shares Held
409M
Call Options Held
7.19M
Put Options Held
6.26M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $173B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Vaughan David Investments LLC Portfolio

Follow Vaughan David Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vaughan David Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vaughan David Investments LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email